1. Home
  2. COLL

COLL

Collegium Pharmaceutical Inc.

Logo Collegium Pharmaceutical Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Founded: N/A Country:
United States
United States
Employees: N/A City: STOUGHTON
Market Cap: 1.2B IPO Year: 2015
Target Price: $38.60 AVG Volume (30 days): 403.7K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 1.29 EPS Growth: N/A
52 Week Low/High: $20.83 - $40.95 Next Earning Date: 05-02-2024
Revenue: $566,767,000 Revenue Growth: 22.17%
Revenue Growth (this year): 5.01% Revenue Growth (next year): 2.13%

Share on Social Networks: